Report of Proposed Sale of Securities (144)
05 Junio 2023 - 5:31PM
Edgar (US Regulatory)
|
Form 144 Filer Information
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 144
NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
|
Form 144 |
144: Issuer Information
| Name of Issuer | LAVA Therapeutics NV |
| SEC File Number | 001-40241 |
| Address of Issuer | YALELAAN 62
UTRECHT
CALIFORNIA
3584 CM |
| Phone | 31 6 3000 3035 |
| Name of Person for Whose Account the Securities are To Be Sold | Novo Holdings A/S |
|
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account
the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given
as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales
for the account of the person filing this notice.
|
| Relationship to Issuer | - 10% Stockholder
|
144: Securities Information
| Record | Title of the Class of Securities To Be Sold | Name and Address of the Broker | Number of Shares or Other Units To Be Sold | Aggregate Market Value | Number of Shares or Other Units Outstanding | Approximate Date of Sale | Name the Securities Exchange |
|---|
|
#1 | Common Stock | Morgan Stanley & Co. LLC
1585 Broadway
New York
NEW YORK
10036 | 670,558 | $1,743,450.80 | 26,289,087 | 06/05/2023 | NASDAQGS |
144: Securities To Be Sold
|
Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment
of all or any part of the purchase price or other consideration therefor:
|
| Record | Title of the Class | Date you Acquired | Nature of Acquisition Transaction | Name of Person from Whom Acquired | Is this a Gift? | Date Donor Acquired | Amount of Securities Acquired | Date of Payment | Nature of Payment * |
|---|
|
#1 | Common Stock | 03/24/2021 | Conversion of Series C Preferred Stock | LAVA Therapeutics N.V. | ☐ |
—
| 874,276 | 03/24/2021 | Conversion of Preferred Stock |
| * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note
thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made
in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.
|
144: Securities Sold During The Past 3 Months
144: Remarks and Signature
| Remarks | |
| Date of Notice | 06/05/2023 |
ATTENTION: |
|
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing
this notice that he does not know any material adverse information in regard to the current and prospective
operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has
adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by
signing the form and indicating the date that the plan was adopted or the instruction given, that person makes
such representation as of the plan adoption or instruction date.
|
| Signature | /s/ Barbara Fiorini Due, General Counsel, Finance & Operations |
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001) |
LAVA Therapeutics NV (NASDAQ:LVTX)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
